AbbVie Q4 Earnings: Strong Performance, Guidance Raised - ABBV

[Para 1: The Lead] AbbVie Inc. (ABBV) exceeded Wall Street earnings expectations in Q4 2026, reporting a 12% increase in earnings per share to $2.50, surpassing analyst forecasts by 15%. The pharmaceutical giant's revenue climbed 8% to $10.5 billion, driven by robust sales of its flagship drugs and successful new product launches. ABBV raised its full-year earnings guidance to $10.20 from $10.00, reflecting strong market demand and operational efficiency. [Para 2-3: Supporting details & Context] The company's earnings per share growth was fueled by a 10% increase in biopharma segment revenue and a 15% jump in global pharmaceuticals sales. ABBV's strong financials are underpinned by a solid balance sheet, with cash and cash equivalents up 10% to $15 billion. The stock closed 3% higher at $135.00 on the news, signaling investor confidence in ABBV's growth trajectory. Analysts anticipate continued momentum in the biopharma sector, with ABBV poised to benefit from ongoing R&D successes and strategic partnerships.